Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $140.9 million.

  • United Therapeutics' Cash from Investing Activities rose 22262.84% to $140.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$446.9 million, marking a year-over-year decrease of 17672.1%. This contributed to the annual value of $417.2 million for FY2024, which is 15797.67% up from last year.
  • United Therapeutics' Cash from Investing Activities amounted to $140.9 million in Q3 2025, which was up 22262.84% from -$299.9 million recorded in Q2 2025.
  • United Therapeutics' 5-year Cash from Investing Activities high stood at $735.3 million for Q1 2024, and its period low was -$359.2 million during Q1 2022.
  • Its 5-year average for Cash from Investing Activities is -$101.3 million, with a median of -$164.7 million in 2025.
  • Per our database at Business Quant, United Therapeutics' Cash from Investing Activities crashed by 560158.73% in 2022 and then skyrocketed by 43256.45% in 2024.
  • United Therapeutics' Cash from Investing Activities (Quarter) stood at -$195.8 million in 2021, then increased by 3.32% to -$189.3 million in 2022, then skyrocketed by 122.24% to $42.1 million in 2023, then plummeted by 392.64% to -$123.2 million in 2024, then skyrocketed by 214.37% to $140.9 million in 2025.
  • Its Cash from Investing Activities was $140.9 million in Q3 2025, compared to -$299.9 million in Q2 2025 and -$164.7 million in Q1 2025.